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Over the past two decades, MRI has come to play a
prominent role in the diagnosis of Alzheimer Dementia
(AD). Findings that have a high sensitivity for AD are
medial temporal lobe atrophy (Fig. 1) and parietal atrophy
(Fig. 2), especially when both are present in the same
patient. If MRI is contraindicated or not available, CT is a
good alternative with which global and medial temporal
lobe atrophy as well as the extent of white matter lesions
may be reliably assessed.
Medial temporal lobe atrophy (MTA) on MRI is now
considered to be one of the three diagnostic criteria for
progression to AD in patients with mild cognitive impair-
ment (MCI), along with temporoparietal hypometabolism
on FDG-PET and tau/amyloid-β in CSF.
Imaging studies have made a large contribution to
insights in how the disease develops. Pathologically, AD
is characterized by the deposition and progressive build-up
of abnormal proteins (amyloid-β and hyper-phosphorylated
tau) in the brain, which interfere with normal function and
cause neuronal and axonal loss. These proteins form
plaques and tangles, initially only affecting the temporal
lobes and limbic system, later spreading to the neocortex.
Atrophy patterns in AD mirror this pattern of abnormal
protein deposition, only at a much later stage in the disease.
Amyloid-β can be detected in vivo using PET using
amyloid-binding compounds such as the 11C-labelled Pitts-
burgh Compound-B (PiB) or 18F-fluorinated variants thereof;
the latter have longer decay-times and will be more suitable
for clinical applications (Fig. 3). These abnormal proteins
which accumulate in the brains of Alzheimer patients may be
present up to 30 years before the manifestation of any
clinical symptoms, and may also be found in normal older
subjects who do not develop dementia. The presence of these
proteins alone are therefore not sufficient for the diagnosis.
Similarly, finding only an abnormally low CSF amyloid level
may not have clinical relevance in the absence of increased
tau (or abnormal MRI).
FDG-PET is another tool which is used in the diagnosis
of AD. Patients with AD typically show hypometabolism in
the temporoparietal, frontal and posterior cingulate cortices
and hippocampus. These findings are highly sensitive
(>90%), but unfortunately not so specific for AD. It can
not always discriminate between AD and other forms of
dementia such as frontotemporal dementia (FTLD) and
dementia with Lewy bodies (DLB). These areas of
hypometabolism may also be seen in patients with MCI—
with good sensitivity (86%) and specificity (96%) in
differentiating these patients from normal subjects. FDG-
PET could therefore be one modality useful in identifying
those patients with MCI that will progress to develop
dementia. Not only is this valuable information for the
patients and their families, it is also becoming increasingly
important to identify early stages of dementia in the light of
potential disease-modifying drugs. Arterial spin-labelling
(ASL) is an upcoming MR technique that may provide
similar information about temporal-parietal hypoperfusion,
without the need of injecting a radio-active tracer
MRI is a useful diagnostic tool in that not only aids in
discriminating different forms of dementia, it is also helpful
in identifying which patients with MCI are likely to
develop AD. As referred to earlier, medial temporal lobe
and parietal atrophy have a positive predictive value in the
diagnosis of AD. In clinical practice, MTA may be assessed
using a visual scale from 0 to 4. Cortical atrophy may be
visually assed using the Global Cortical Atrophy Scale
(0–3). Discordant parietal atrophy, particularly of the
precuneus, is also characteristic of AD, especially in the
presenile variant when medial temporal lobe atrophy
may not be present. MR images of patients with AD
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Fig. 2 Sagittal and coronal
T1-weighted images of an
early-onset AD patient with
precuneus/parietal atrophy (left).
Note that there is no medial
temporal lobe atrophy (right)
Fig. 3 Positive (left) and
negative (right) PiB-PET studies
with classic AD frontotemporal
uptake on the left
Fig. 1 Coronal T1-weighted image showing medial temporal lobe
atrophy, with profound volume loss on the left
MRI FDG hypometabolism PiB binding Dopamine SPECT
AD medial temporal lobe,
parietal atrophy
frontotemporal and
posterior cingulum
yes normal
FTLD (asymmetric) frontal and/or
temporal atrophy
frontal no normal
DLB parietal and/or occipital atrophy occipital possible decreased binding
basal ganglia
Table 1 Overview of findings
on MRI and molecular imaging
in differentiating AD from
FTLD and DLB
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may also show white matter hyperintensities and micro-
bleeds. The main differentials of AD are FTLD and
DLB, with partially overlapping MRI features. Table 1.
provides an overview of how these may be differentiated
using additional (molecular) imaging. Figure 4 shows a
theoretical model of the natural progression of cognitive
and biological markers in AD.
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Fig. 4 Theoretical model dem-
onstrating cognitive and biolog-
ical markers in the natural
progression of AD (reprinted
with permission from Frisoni, G.
B. et al. Nat. Rev. Neurol.
2010:6, 67–77)
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